296 related articles for article (PubMed ID: 18519810)
1. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
Gurer C; Strowig T; Brilot F; Pack M; Trumpfheller C; Arrey F; Park CG; Steinman RM; Münz C
Blood; 2008 Aug; 112(4):1231-9. PubMed ID: 18519810
[TBL] [Abstract][Full Text] [Related]
2. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.
Leung CS; Maurer MA; Meixlsperger S; Lippmann A; Cheong C; Zuo J; Haigh TA; Taylor GS; Münz C
Blood; 2013 Feb; 121(9):1584-94. PubMed ID: 23297134
[TBL] [Abstract][Full Text] [Related]
3. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
4. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G; Münz C
J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
[TBL] [Abstract][Full Text] [Related]
5. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
6. T-Lymphocyte Activation Is Correlated With the Presence of Anti-EBV in Patients With Laryngeal Squamous Cell Carcinoma.
Klatka J; Hymos A; Szkatuła-Łupina A; Grywalska E; Klatka B; Terpiłowski M; Stepulak A
In Vivo; 2019; 33(6):2007-2012. PubMed ID: 31662531
[TBL] [Abstract][Full Text] [Related]
7. Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.
Rühl J; Citterio C; Engelmann C; Haigh T; Dzionek A; Dreyer J; Khanna R; Taylor GS; Wilson JB; Leung CS; Münz C
J Clin Invest; 2019 May; 129(5):2071-2087. PubMed ID: 31042161
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
[TBL] [Abstract][Full Text] [Related]
9. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
[TBL] [Abstract][Full Text] [Related]
10. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals.
Njongmeta LM; Bray J; Davies CJ; Davis WC; Howard CJ; Hope JC; Palmer GH; Brown WC; Mwangi W
Vaccine; 2012 Feb; 30(9):1624-35. PubMed ID: 22240344
[TBL] [Abstract][Full Text] [Related]
11. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.
Long HM; Chagoury OL; Leese AM; Ryan GB; James E; Morton LT; Abbott RJ; Sabbah S; Kwok W; Rickinson AB
J Exp Med; 2013 May; 210(5):933-49. PubMed ID: 23569328
[TBL] [Abstract][Full Text] [Related]
12. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
14. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
[TBL] [Abstract][Full Text] [Related]
15. Contrasting roles of dendritic cells and B cells in the immune control of Epstein-Barr virus.
Bickham K; Münz C
Curr Top Microbiol Immunol; 2003; 276():55-76. PubMed ID: 12797443
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M; Paludan C; Tsang ML; Mahnke K; Steinman RM; Münz C
J Exp Med; 2001 Feb; 193(3):405-11. PubMed ID: 11157061
[TBL] [Abstract][Full Text] [Related]
17. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
18. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
Lünemann JD; Jelcić I; Roberts S; Lutterotti A; Tackenberg B; Martin R; Münz C
J Exp Med; 2008 Aug; 205(8):1763-73. PubMed ID: 18663124
[TBL] [Abstract][Full Text] [Related]
19. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.
Jones K; Nourse JP; Morrison L; Nguyen-Van D; Moss DJ; Burrows SR; Gandhi MK
Blood; 2010 Sep; 116(13):2245-52. PubMed ID: 20562330
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
